INTRODUCTION
Aldolase B is an enzyme involved in both glycolytic and gluconeogenic pathways. Expression of the aldolase B gene occurs in the adult liver, proximal tubules of the kidney and small intestine. In the rat liver, it is subjected to a nutrient and hormonal regulation: its transcription is activated by glucose and insulin and inhibited by glucagon and cyclic AMP (1) . A 200 bp (-194 to +14) proximal promoter fragment is sufficient to confer a tissue-specific but low expression on a reporter gene in transient transfection assays (2) . This promoter can be stimulated, ex vivo (2) We previously demonstrated that DBP (in hepatoma cells) and HNF1 were potent transactivators of the aldolase B promoter while HNF3 competitively antagonized HNF 1-dependent transactivation (5) . Consequently, we hypothesized that the low activity of the aldolase B proximal promoter in hepatocytes and hepatoma cells could be due to the abundance of HNF3 in those cells, competing with HNF1 for binding to the PAB region. Indeed, we found that, in in vitro DNase 1 foootprinting experiments using liver nuclear extracts, HNF3 was preferentially bound to the PAB element (4). However, this hypothesis implied that HNF3, reported to be a transactivator of several hepatic genes (6-9), behaved as an 'anti-activator' in the context of the aldolase B promoter. In this paper we present evidence that, indeed, replacement of the region PAB by an exclusive HNF 1 binding site, unable to bind HNF3, resulted in a strong stimulation of the aldolase B promoter activity in Hep G2 cells, while replacement of this region by a consensus HNF3 binding site did not significantly modify the low activity of the wild-type promoter. The distal transactivator DBP similarly activated the promoters whatever factor they bind in the region of the PAB element. These results indicates that the aldolase B promoter is normally restrained in liver-type cells by HNF3 independently of the transactivation by proteins of the C/EBP-DBP family.
MATERIALS AND METHODS
Cell culture and transient transfections. Monolayers of human hepatoma (Hep G2) cells were maintained in Dubellcco's modified medium (DMEM) supplemented with 10% (vol/vol)
To whom correspondence should be addressed fetal calf serum, 1 /tM L-triiodothyronin, 1 nM dexamethasone, 10 nM insulin. Cells were plated at a density of 10 6 per 28 cm 2 dish. Transfection was carried out by the calcium phosphate method (10) . Each dish received a total of 12 ng of DNA including 2 tig of the pRSV luciferase standardization plasmid that was used to monitor variations in transfection efficiency. Calcium phosphate precipitate was removed at the 18th hour, the cells were fed fresh medium, cultured further for 40 hours and then harvested for chloramphenicol acetyltransferase (CAT) assay (11) and luciferase assay (12) as described.
Cotransfection experiments
The DBP expression vector (pRSV-DBP) was kindly provided by U.Schibler (13) , the HNF1 expression vector (pRSV-HNFl) by M.Yaniv (14) and the HNF3a expression vector (pRSVHNF3a) by R.Costa (15, 16) . Cotransfections were performed with 7.5 ng of the tested plasmid, 2.5 /tg of the expression vector CAT activity was normalized with respect to the transfection efficiency by measuring the luciferase activity. The results presented are the mean of at least 3 independent assays, and are given ± SD; activity of the HNF3.HNF1-83 plasmid has been measured only twice.
and 2 /tg of the pRSV luciferase standardization plasmid, for a total DNA amount of 12 ng per dish.
Construction of vectors
The -83 aldolase B/CAT construct was obtained by subcloning a PCR fragment of the aldolase B promoter spanning from nt -83 to +14 into the previously described Pe CAT plasmid (2) The other constructs used have been previously described (2,5). All constructs were checked by DNA sequencing.
RESULTS

The HNFl-dependent transactivation of the aldolase B promoter is restrained by HNF3 in HepG2 cells
We previously suggested that the low efficiency of the proximal aldolase B promoter in transiently transfected hepatocytes or hepatoma cells was due to the dual binding activity of the PAB region, able to bind on a mutually exclusive mode either HNF 1 or HNF3 (4, 5) , as demonstrated by gel shift assays using either liver or Hep G2 cell nuclear extracts (4) . Indeed, in the context of this promoter, HNF1 is a strong transactivator while HNF3, abundant in the liver and differentiated hepatoma cells, is not, and thus impairs the HNFl-dependent transactivation (5). We also reported that the proximal promoter incubated in vitro with liver nuclear extracts bound HNF3 rather than HNF 1 on the PAB region (4). This hypothesis implies that replacing the PAB region by an exclusive HNF 1 binding site should strongly stimulate the promoter activity while replacing this region by an exclusive HNF3 binding site should be without any effect, except to unable HNFl to transactivate the promoter.
To test this hypothesis we designed truncated aldolase B promoter fragments consisting of either the L-type pyruvate kinase gene HNFl binding site, or the transthyretin gene HNF3 binding site, or both HNF3 and HNFl binding sites placed in front of the -83 construct. Activity of these plasmids was compared to that of a construct in which the PAB region itself was ligated upstream of the -83 construct. The constructs of the -83 series are devoid of the proximal element (PE) identified by in vitro DNAse 1 footprinting experiments in the wild-type promoter (4) . Fig. 1 shows that the activity of the -126, -113 and -83 aldolase B CAT constructs in transiently transfected Hep G2 cells was similarly low. As expected, ligation of the aldolase B PAB region upstream of the -83 fragment did not modify this activity (note that -126 and PAB-83 constructs only differ by the presence or the absence of the element PE). Ligation of the exclusive HNF3 binding site in front of the -83 sequence did not significantly change the promoter activity, while ligation of the exclusive HNF 1 binding site stimulated this activity by about 30 fold, in full accordance with our hypothesis. Activity of HNF3,HNFl-83 construct was similar to that of the HNF 1-83 plasmid.
These results were confirmed with constructs in which the binding sites for NFY, C/EBP-DBP and the element DE have been added upstream of the HNF 1-83, HNF3-83 and PAB-83 constructs, giving the HNF1-, HNF3-and PAB-190 series (Fig.  1) . However, the HNF 1-190 construct was 2.5 fold less active than the HNF 1-83 construct, probably because of the presence of negative elements, especially DE and, perhaps, the NFY binding site (5) . over-expressed under the direction of the pRSV-HNFl expression vector. Indeed, a -83/+14 fragment was able to bind recombinant HNF la produced in a baculovirus-dependent system (a gift from F.Tranche and M.Yaniv), but not endogenous HNFl from liver nuclear extracts (data not shown), indicating the presence in this fragment of a cryptic low affinity HNFl binding site. Accordingly, the HNF3-83 construct was also slightly stimulated by HNFl. The PAB-83 construct was strongly stimulated (about 120 fold) by HNFl, as this has been reported for the -190 wild-type construct. This is probably due to the ability of a high HNFl concentration to displace HNF3 bound to PAB. The HNF 1-83 construct, that is by itself 30 fold more active than the other constructs, is much less stimulated by HNF 1 (about 5 fold only), probably because the L-type pyruvate kinase gene exclusive HNF 1 binding site of this construct is already saturated by the endogenous HNFl of Hep G2 cells. However, the stimulation by HNFl over-expression was 2-3 fold higher for the HNF 1-190 than for the HNF 1-83 plasmid (not shown), suggesting that the negative elements contained in the -190/-122 fragment could interfere with HNFl binding at physiological concentration. Indeed, we have previously suggested that NFY could impair binding of HNFl on the immediately downstream binding site (5) .
DBP-dependent transactivation is independent of the binding activity on the PAB region
The -170/-140 element binds proteins of the C/EBP-DBP family and, in Hep G2 cells, mediated a 25 fold transactivation by over-expressed DBP (5). Fig. 3 shows that a similar 15-37 fold activation by DBP was observed for the wild-type -190 plasmid, the HNF1-, HNF3 and PAB-190 series and the -190 'mut' plasmid whose PAB element is mutated by replacement of six bases (5). These results confirm our previous features that HNFl and DBP-dependent transactivations of the -190 construct are additive and indicate that the DBP action is independent of the complex assembled on the PAB region. 
DISCUSSION
All results reported in this paper are consistent with a model in which the unique features of the PAB motif, binding either HNFl or HNF3, play a major role in the activity of the aldolase B gene promoter. Since HNF3 proteins appear before HNFla in endodermal tissues (18) , a high HNF3/HNF1 ratio in fetal liver could contribute to repress aldolase B gene expression while the major aldolase isozyme synthesized is aldolase A. HNFla, a homeodomain transcription factor, has been reported to be a major transactivator of numerous liver-specific genes (7, (19) (20) (21) (22) (23) , and is also a strong activator of the aldolase B promoter. However, in the liver and differentiated hepatoma cell lines, HNF3, in fact corresponding to several monomeric proteins of the growing Forkhead family (16), competes with HNFl for binding to PAB.
HNF3 binding sites have been identified as essential deactivating element in the promoters and (or) enhancers of several liver-specific genes, for instance the genes for al-antitrypsin, transthyretin (19) , tyrosine aminotransferase (24) , apolipoprotein B (9) and albumin (8) . However, the transactivation by HNF3 of an HNF3-dependent minimal promoter is relatively low ; it does not exceed 4 fold (25) , as compared to more than 100 fold with HNFl (14, 26, 27) . Several papers report that an important role of HNF3 could be to cooperate with other factors bound to contiguous DNA elements. For instance, a close cooperation betweenHNF3 and the glucocorticoid receptor has been reported in the glucocorticoid responsive enhancer of the tyrosine aminotransferase gene (24) , between HNF3 and nuclear factor 1 (NF1) in the albumin gene enhancer (8) , and between HNF3 and proteins of the HNF4/ARP1/COUP-TF family in the apolipoprotein gene enhancer (9) . In the aldolase B promoter, we find another exemple of a functional interaction between HNF3 and another transcription factor, namely an antagonistic interaction with HNF1. An aldolase B promoter possessing an exclusive HNF3 binding site instead of the element PAB is poorly active when transiently transfected in Hep G2 cells, and is not transactivated by a HNF3 expression vector, which signifies that HNF3 is not by itself a transactivator in the context ot the aldolase B promoter. Instead, it behaves as an inhibitor since it restrains the promoter of being activated by HNF 1. This inhibitory effect of HNF3 on HNFl-dependent transactivation is totally dependent on the competition between these factors for binding to overlapping sites since replacement of the composite PAB site by contiguous non overlapping sites for HNF3 and HNFl (HNF3.HNF1-83 construct) lead to an activity as high as with the HNF 1-83 promoter. An apparent paradox is that the proximal aldolase B promoter is so severely restrained by HNF3 when tested in transiently transfected Hep G2 cells while the aldolase B gene is strongly expressed in vivo. In fact, the activator located in the first intron of the aldolase B gene is needed for this high expression in vivo (unpublished data). We can hypothesize that the interaction between the promoter and the intronic activator is capable of overriding the HNF3-dependent inhibition of the gene. The question can be raised of whether HNF3 itself, in fact, is important for this interaction. In the transthyretin gene, for instance, a high affinity HNF3 binding site located in the promoter is necessary for the activation by a distal enhancer ; in this gene, however, in contrast with our results on the aldolase B promoter, the HNF3 site is also essential to the promoter activity in the absence of enhancer (7) . Very recently, HNF3 has been proposed to play a role in the transition of chromatin from an inactive to an active conformation (28) . In the case of the aldolase B gene, binding of HNF3 to the PAB element in some early fetal tissues could contribute to open chromatin around the aldolase B promoter, therefore making it permissive for subsequent HNF 1 binding and transcriptional activation.
Ci's-acting elements located upstream of the PAB motif can also modulate the promoter activity, as previously reported (5) while the PE box identified by DNAse 1 footprinting and located downstream of PAB seems dipensable in our experimental system. As a whole, the upstream -190/-122 fragment decreases the activity of the strongly active HNF 1-83 plasmid, perhaps due to a partial steric hindrance between NFY and HNFl bound to closely apposed sites (4) . Accordingly, HNFl hyperexpression allows to restore full activity of the promoter.
The C/EBP-DBP site has been shown to be especially sensitive to DBP in Hep G2 cells. In the present paper, we show that the transactivation by DBP is largely independent on the nature of the element at the PAB position, and thus of the factor bound to this element. Rather, proteins of the C/EBP-DBP family could interact with the transcription initiation complex (directly or through auxiliary /bridging factors (29-31), and does not act primarily by modifying the ratio of HNF 1 to HNF3 bound to PAB. This explains our earlier observation that transactivations by HNFl and DBP expression vectors are additive (5).
In conclusion, our results emphasize a new type of functional interaction between HNF3 and another factor, here the antagonism with HNFl that maintains the aldolase B promoter under a negative constraint in tissues where both HNFl and HNF3 are present (that is to say, endodermal derivatives of the primitive gut) (32) . To determine how this negative constraint is over-come in vivo and what is the role of the intronic activator in this phenomenon require further investigations which are currently under way.
